SLC5A2 and diabetes mellitus: Recent studies have shown the protective effect of SGLT2 inhibitors (canagliflozin, empagliflozin, and dapagliflozin) against cardiovascular disease and death in patients with type 2 diabetes mellitus (Wiviott et al., 2019a; Arnott et al., 2020); however, oral admission of canagliflozin could increase the risk of limb amputation (Matthews et al., 2019), while both dapagliflozin and empagliflozin exhibit no evidence of risk (Dicembrini et al., 2019).